^
Association details:
| Biomarker: | BRCA wild-type |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) + Lynparza (olaparib) (PARP inhibitor) + Imfinzi (durvalumab) (PD-L1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Durvalumab with paclitaxel/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumor BRCA1/2 mutation (non-tBRCAm): Results from the randomized, placebo (pbo)-controlled phase III DUO-O trial.
Published date:
05/25/2023
Excerpt:
PC + bev + durva followed by mtx bev + durva + ola in pts with newly diagnosed non-tBRCAm AOC resulted in a statistically significant and clinically meaningful improvement in PFS vs PC + bev followed by mtx bev.
Secondary therapy:
carboplatin + paclitaxel
DOI:
10.1200/JCO.2023.41.17_suppl.LBA5506
Trial ID:
